

Pierre-Louis Tharaux^{1,2,3,4} and Tobias B. Huber^{4,5,6}

How Is Proteinuric Diabetic Nephropathy Caused by Disturbed Proteostasis and Autophagy in Podocytes?



Diabetes 2016;65:539–541 | DOI: 10.2337/dbi15-0026

Progression of diabetic nephropathy (DN) is commonly defined by an increase in albuminuria from normoalbuminuria to microalbuminuria and from microalbuminuria to macroalbuminuria. Although many therapeutic interventions, including reducing hyperglycemia and intraglomerular pressure, have been shown to slow down the progression of DN, many patients still develop end-stage renal disease. A major difficulty in inducing remission in patients with early DN is the identification of biomarkers that could help to identify patients more likely to progress to end-stage renal disease. Traditional risk factors, such as albuminuria, do not effectively predict DN progression, and other predictors of DN have yet to be characterized and validated. The need for discovering sensitive and robust biomarkers to monitor the decline in renal function and to separate progressors from nonprogressors of DN is therefore of paramount importance.

Next to mesangial extracellular matrix deposition and a thickening of basement membranes, progressive loss of glomerular pericytes and “podocytes” and microvascular alterations appear to most closely correlate with the functional renal decline in DN (1–3).

Autophagy (“self-eating” in Greek) is a highly regulated lysosomal protein degradation pathway that removes protein aggregates and damaged or excess organelles in order to maintain intracellular homeostasis and cell integrity (4–6). This process was first described in 1957 by Sam Clark Jr. (7), but the term “autophagy” was coined in 1963 by Christian de Duve (8). Autophagy process is well conserved in the evolution from yeast to mammals in various cell types in many organs (9,10). The formation of autophagosomes

depends on several genes including *Map1lc3B/LC3B*, *Becn1/Beclin-1*, and other autophagy-related (*Atg*) genes (4). Dysregulation of autophagy is involved in the pathogenesis of a variety of metabolic and age-related diseases (11–17). One caveat of many clinical studies dealing with tissues that should be taken into consideration is that there is a general tendency to extrapolate information regarding the levels of autophagy substrates to the levels of autophagy flux within the tissues. Despite the scarce but compelling literature on the roles of autophagy in the resistance to DN, studies need to determine whether autophagy genes and markers are suitable biomarkers or targets for therapeutic intervention to ameliorate the progression of DN. Future research would ultimately determine the most reliable method for alterations of autophagy related to DN progression, taking ease and quantity of sample acquisition into account.

The function of autophagy in the kidneys is currently under investigation, and it has been shown to have a renoprotective effect in several animal models of aging and acute kidney injury, especially in glomeruli (18–21). Importantly, postmitotic podocytes exhibit high levels of basal autophagy as a key regulator of podocyte and glomerular maintenance (22) (Fig. 1).

In this issue of *Diabetes*, Tagawa et al. (23) confirm the protecting role of podocyte autophagy on DN, as selective targeting of the *Atg5* alleles in these cells accentuated experimental high-fat diet-induced DN as previously observed in a model of type 1 DN (24). Furthermore, it is interesting that the loss of autophagy in podocytes affects the ultrastructure and function of these cells but also that

¹Paris Cardiovascular Centre, INSERM, Paris, France

²Université Paris Descartes, Sorbonne Paris Cité, Paris, France

³Nephrology Service, Georges Pompidou European Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France

⁴FRIAS, Freiburg Institute for Advanced Studies and Center for Biological System Analysis-ZBSA, Freiburg, Germany

⁵Renal Division, University Hospital Freiburg, Freiburg, Germany

⁶BIOSS Center for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany

Corresponding author: Pierre-Louis Tharaux, pierre-louis.tharaux@inserm.fr, or Tobias B. Huber, tobias.huber@uniklinik-freiburg.de.

© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

See accompanying article, p. 755.




Figure 1—Postmitotic podocytes exhibit high levels of basal autophagy as a key regulator of podocyte and glomerular maintenance. Elevation of glucose concentration inhibits podocyte autophagy (–). Selective targeting of the *Atg5* alleles in these cells disrupted autophagosome formation and accentuated experimental high-fat diet-induced DN. Altered autophagy led to accumulation of damaged organelles and proteins and disturbance of lysosomes trafficking. Furthermore, insufficient podocyte autophagy was found in diabetic patients and rats with massive proteinuria accompanied by podocyte loss, but not in those with no or minimal proteinuria. The nature of the negative signal associated with albuminuria is not known. Endocytosed albumin (green dots) per se may saturate podocyte autophagy or albuminuria may be associated with local passage or secretion of inhibitory mediators (purple dots) that remain to be identified. Such circulating mediator may also impact endothelial autophagy that has also been shown to limit progression of experimental DN. Red dots represent phosphatidyl-ethanolamine-conjugated microtubule-associated protein 1A/1B-light chain 3 (LC3), which is recruited to autophagosomal membranes and helps to monitor autophagy flux. EC, endothelial cells; GBM, glomerular basement membrane.

of nearby mesangial cells, which become sclerotic. These data underline the communication between podocytes and mesangial cells, which deserve further studies in the field of glomerular diseases.

Importantly, Tagawa et al. (23) also show insufficient podocyte autophagy in patients with diabetes and rats with massive proteinuria accompanied by podocyte loss but not in those with no or minimal proteinuria. The causes of such alteration of podocyte autophagy are potentially several. Meanwhile, stimulation of cultured podocytes with sera from patients with diabetes or rats with massive proteinuria-impaired autophagy resulted in apoptosis. These findings might be of crucial importance as they suggest the existence of serum factors promoting podocyte stress and dysfunction with blunting of autophagy in proteinuric individuals. Let us hope this provocative finding will lead to future work aimed at identifying such factors. Another question rising from the study by Tagawa et al. is whether inhibition of autophagy by serum from proteinuric diabetic animals or patients with diabetes would also occur in other critical cell types such as endothelial cells. In fact, endothelial autophagy was recently

shown to be of critical importance for the limitation of progression of DN (24). There is a strong relationship between endothelial dysfunction and DN in humans (25,26), and an increase in urinary albumin excretion in combination with rising blood pressure is a major risk factor for cardiovascular morbidity (27–30). The mechanism for such cross talk between the glomerular filtration barrier and other vascular beds is unclear and represents a major pathophysiological question.

Fundamentally, the work by Tagawa et al. (23) also adds a major question mark about the pathophysiological importance of protein homeostasis, also called “proteostasis,” in terminally differentiated cells such as podocytes. Different mechanisms are involved in proteostasis, among them degradation systems (the main intracellular proteolytic systems being proteasome and lysosomes), folding systems (including molecular chaperones), and enzymatic mechanisms of protein repair (31). Tagawa et al. report the accumulation of large lysosomes with an increase in lamp2-positive areas and an absence of autophagosomes in podocytes from massively proteinuric and diabetic rats and in mice with genetic targeting of *Atg5*, a gene required for autophagy. Thus, metabolically and genetically driven autophagy deficiency was associated with dysfunctional lysosomes accumulated in podocytes. The preservation of lysosome- and autophagy-mediated proteostasis may be critical for podocytes to cope with increased amounts of damaged proteins produced during diabetes, a condition favoring increased intensity of nonenzymatic modifications of amino acids (32) and high incidence of posttranslational modifications of proteins as reported in β -cells and nerves (33,34).

In conclusion, the study by Tagawa et al. (23) adds to the recent corpus of evidence that therapeutic stimulation or at least maintenance of autophagy and proteostasis represents an important nascent field of research to prevent and treat complications of diabetes.

Funding. This work was supported by INSERM (to P.-L.T.), the Joint Transnational Call 2011 for “Integrated Research on Genomics and Pathophysiology of the Metabolic Syndrome and the Diseases arising from it” from L’Agence Nationale de la Recherche of France (to P.-L.T.), and the German Research Foundation (to T.B.H.). This study was further supported by the German Research Foundation’s SFB 1140 Kidney Disease—From Genes to Mechanisms, Heisenberg program, and grant CRC 992 (to T.B.H.); by the European Research Council (to T.B.H.); and by the Excellence Initiative of the German Federal and State Governments (EXC 294 to T.B.H.).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

References

- Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor- β antibody in db/db diabetic mice. *Proc Natl Acad Sci U S A* 2000;97:8015–8020
- Ziyadeh FN. Mediators of diabetic renal disease: the case for tgf- β as the major mediator. *J Am Soc Nephrol* 2004;15(Suppl. 1):S55–S57
- Najafian B, Alpers CE, Fogo AB. Pathology of human diabetic nephropathy. *Contrib Nephrol* 2011;170:36–47

4. Boya P, Reggiori F, Codogno P. Emerging regulation and functions of autophagy. *Nat Cell Biol* 2013;15:713–720
5. Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. *N Engl J Med* 2013;368:1845–1846
6. Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. *J Pathol* 2010;221:3–12
7. Clark SL Jr. Cellular differentiation in the kidneys of newborn mice studies with the electron microscope. *J Biophys Biochem Cytol* 1957;3:349–362
8. de Duve C. The lysosome: attempt at a historical and evolutionary outline. *Arch Biol (Liege)* 1980;91:175–191 [in French]
9. Mikles-Robertson F, Dave C, Porter CW. Apparent autophagocytosis of mitochondria in L1210 leukemia cells treated in vitro with 4,4'-diacetyl-diphenylurea-bis(guanyldiphenylhydrazone). *Cancer Res* 1980;40:1054–1061
10. Novikoff AB, Shin WY. Endoplasmic reticulum and autophagy in rat hepatocytes. *Proc Natl Acad Sci U S A* 1978;75:5039–5042
11. Shibata M, Lu T, Furuya T, et al. Regulation of intracellular accumulation of mutant Huntingtin by Beclin 1. *J Biol Chem* 2006;281:14474–14485
12. Yang Z, Klionsky DJ. Eaten alive: a history of macroautophagy. *Nat Cell Biol* 2010;12:814–822
13. Singh R, Xiang Y, Wang Y, et al. Autophagy regulates adipose mass and differentiation in mice. *J Clin Invest* 2009;119:3329–3339
14. Rubinsztein DC, Mariño G, Kroemer G. Autophagy and aging. *Cell* 2011;146:682–695
15. Meléndez A, Tallóczy Z, Seaman M, Eskelinen EL, Hall DH, Levine B. Autophagy genes are essential for dauer development and life-span extension in *C. elegans*. *Science* 2003;301:1387–1391
16. Lipinski MM, Zheng B, Lu T, et al. Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer's disease. *Proc Natl Acad Sci U S A* 2010;107:14164–14169
17. Jia G, Cheng G, Agrawal DK. Autophagy of vascular smooth muscle cells in atherosclerotic lesions. *Autophagy* 2007;3:63–64
18. Kume S, Thomas MC, Koya D. Nutrient sensing, autophagy, and diabetic nephropathy. *Diabetes* 2012;61:23–29
19. Kume S, Uzu T, Maegawa H, Koya D. Autophagy: a novel therapeutic target for kidney diseases. *Clin Exp Nephrol* 2012;16:827–832
20. Huber TB, Edelstein CL, Hartleben B, et al. Emerging role of autophagy in kidney function, diseases and aging. *Autophagy* 2012;8:1009–1031
21. Weide T, Huber TB. Implications of autophagy for glomerular aging and disease. *Cell Tissue Res* 2011;343:467–473
22. Hartleben B, Gödel M, Meyer-Schwesinger C, et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. *J Clin Invest* 2010;120:1084–1096
23. Tagawa A, Yasuda M, Kume S, et al. Impaired podocyte autophagy exacerbates proteinuria in diabetic nephropathy. *Diabetes* 2016;65:755–767
24. Lenoir O, Jasiak M, Héniqne C, et al. Endothelial cell and podocyte autophagy synergistically protect from diabetes-induced glomerulosclerosis. *Autophagy* 2015;11:1130–1145
25. Jawa A, Nachimuthu S, Pendergrass M, Asnani S, Fonseca V. Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin-converting enzyme inhibitor therapy. *J Clin Endocrinol Metab* 2006;91:31–35
26. Nakagawa T, Tanabe K, Croker BP, et al. Endothelial dysfunction as a potential contributor in diabetic nephropathy. *Nat Rev Nephrol* 2011;7:36–44
27. Gerstein HC, Mann JF, Yi Q, et al.; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non-diabetic individuals. *JAMA* 2001;286:421–426
28. Jarrett RJ, Viberti GC, Argyropoulos A, Hill RD, Mahmud U, Murrells TJ. Microalbuminuria predicts mortality in non-insulin-dependent diabetics. *Diabet Med* 1984;1:17–19
29. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. *N Engl J Med* 1984;310:356–360
30. Lane JT. Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective. *Am J Physiol Renal Physiol* 2004;286:F442–F450
31. Jaisson S, Gillery P. Impaired proteostasis: role in the pathogenesis of diabetes mellitus. *Diabetologia* 2014;57:1517–1527
32. Newsholme P, Rebelato E, Abdulkader F, Krause M, Carpinelli A, Curi R. Reactive oxygen and nitrogen species generation, antioxidant defenses, and β -cell function: a critical role for amino acids. *J Endocrinol* 2012;214:11–20
33. Dunne JL, Overbergh L, Purcell AW, Mathieu C. Posttranslational modifications of proteins in type 1 diabetes: the next step in finding the cure? *Diabetes* 2012;61:1907–1914
34. McLean WG, Pekiner C, Cullum NA, Casson IF. Posttranslational modifications of nerve cytoskeletal proteins in experimental diabetes. *Mol Neurobiol* 1992;6:225–237